Regulatory Story
Go to market news section View chart   Print
RNS

Payment From Janssen Pharmaceuticals

Released 07:00 09-Oct-2013

RNS Number : 0697Q
Hutchison China Meditech Limited
09 October 2013
 



 

 

 

 

Hutchison China MediTech Limited ("Chi-Med")

(AIM: HCM)

 

 

Candidate Nomination of Novel Small-Molecule Therapy in Inflammation Triggers Milestone Payment From Janssen Pharmaceuticals, Inc.

 

London: Wednesday, 9 October 2013:  Chi-Med today announces that Hutchison MediPharma Limited ("HMP"), its majority owned R&D company, is set to receive a milestone payment of US$6 million from Janssen Pharmaceuticals, Inc. ("Janssen"), pursuant to the global strategic alliance (the "Agreement") to develop novel small-molecule therapeutics against a target in the area of inflammation/immunology entered into by the companies in June 2010.

The US$6 million milestone was triggered by a compound, the Candidate, discovered by HMP in collaboration with Janssen meeting certain development candidate criteria pursuant to the Agreement.  Upon achievement of specific clinical development and approval milestones, HMP may potentially receive up to an additional US$90.5 million and is entitled to royalties on worldwide sales upon commercialisation of a product by Janssen.

 

Ends

Enquiries

Chi-Med

Christian Hogg, CEO

Telephone:      +852 2121 8200

 

 

 

Citigate Dewe Rogerson

Anthony Carlisle

David Dible

Telephone:      +44 20 7638 9571

Mobile:             +44 7973 611 888

Mobile:             +44 7967 566 919

 

 

Panmure Gordon (UK) Limited

Richard Gray

Andrew Potts

Telephone:      +44 20 7886 2500

Notes to Editors

About HMP

HMP is a novel drug R&D company focusing on discovering, developing and commercialising innovative therapeutics in oncology and autoimmune diseases.  With a team of around 200 scientists and staff, its pipeline is comprised of novel oral compounds for cancer and inflammation in development in North America, Europe, Australia and Greater China. 

HMP is majority owned by Chi-Med.  For more information please visit:  www.hmplglobal.com

About Chi-Med

Chi-Med is the holding company of a healthcare group based primarily in China and was listed on the Alternative Investment Market of the London Stock Exchange in May 2006.  It is focused on researching, developing, manufacturing and selling pharmaceuticals and health oriented consumer products.

Chi-Med is majority owned by Hutchison Whampoa Limited, an international company listed on the Main Board of The Stock Exchange of Hong Kong Limited.  For more information please visit: www.chi-med.com

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCGUBDGXSGBGXC
Close


London Stock Exchange plc is not responsible for and does not check content on this Website. Website users are responsible for checking content. Any news item (including any prospectus) which is addressed solely to the persons and countries specified therein should not be relied upon other than by such persons and/or outside the specified countries. Terms and conditions, including restrictions on use and distribution apply.

 


Payment From Janssen Pharmaceuticals - RNS